Press Releases All News 2019 2018 2017 2016 2015 2014 Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference February 15, 2017 Relmada Therapeutics to Participate in BIO CEO and Investor Conference February 13, 2017 Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone January 25, 2017 Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER January 24, 2017 Relmada Therapeutics to Present at Biotech Showcase 2017 January 5, 2017 Relmada Therapeutics to Present at LD Micro "Main Event" Investor Conference November 29, 2016 Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention October 27, 2016 Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms October 19, 2016 Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum October 6, 2016 Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston September 28, 2016 « Previous 1 2 3 4 5 6 7 8 9 10 ...13 Next »
Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference February 15, 2017
Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone January 25, 2017
Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention October 27, 2016
Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms October 19, 2016
Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston September 28, 2016